mynth
← DATABASE
04/2026

VISIONIX INTERNATIONAL acquired by REVENIO GROUP CORPORATION

FRANCE Life Sciences / Medical Devices / Diagnostic Equipment EV 300M - 700M EUR

Context

The group has finalized a definitive agreement to acquire the entire share capital of the target, a maneuver designed to fundamentally expand its presence as a turnkey provider in the global eye care market. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading technical operational depth in refraction and finishing with the group’s established leadership in tonometry and imaging. This fusion effectively creates a specialized powerhouse in the ophthalmic arena, providing the organization with the scientific talent and technological hardware required to address the increasing complexity of diagnostic and optical retail workflows. The operation allows the group to execute a definitive structural expansion of its total addressable market, specifically targeting high-growth segments such as Optical Coherence Tomography (OCT). By incorporating the target's innovative product suite, the organization can now provide a more robust and integrated solution set for professionals across optometry, retail, and ophthalmology.

VISIONIX INTERNATIONAL, which reported an EBITDA margin of in 2025, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Visionix International operates as a premier technology organization dedicated to the engineering and distribution of advanced ophthalmic diagnostic and optical technologies. The entity’s business model is centered on a proprietary framework of high-performance refraction, screening, and lens finishing solutions designed to optimize clinical and retail workflows. Its value proposition is anchored in technical operational depth, providing integrated hardware and software platforms that facilitate precise vision correction and early disease detection. Strategically, the firm focuses on the deployment of automated diagnostic systems and telehealth-enabled solutions to address the evolving needs of the optical retail and optometry segments. By maintaining a specialized focus on technical innovation and industrialized quality standards, the organization ensures a vital role in the structural advancement of vision care accessibility.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2025
2024

Similar deals in Life Sciences

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
DateAcquirerTargetCountrySector
06/2026BRIDGEPOINTOBAGI MEDICALUNITED STATESGenerics / Labs
05/2026STRYKERAMPLITUDE VASCULAR SYSTEMSUNITED STATESMedical Devices
04/2026FOR TALENTS / UI INVESTISSEMENT / GENEONEFTYS PHARMAFRANCEAnimal Health
04/2026OURY MEDICALCÉFIMÉCAFRANCEImplants & Prosthetics
04/2026Gilead SciencesArcellxUNITED STATESR&D Biotech
04/2026FINE FOODS & PHARMACEUTICALSSOFARITALYCDMO
04/2026AMERICAN INDUSTRIAL PARTNERS AIPAVANOS MEDICALUNITED STATESMedical Consumables
04/2026RANTUM CAPITALTONTARRA MEDIZINTECHNIKGERMANYMedical Devices
04/2026UCBNEURONA THERAPEUTICSUNITED STATESR&D Biotech
04/2026HALMASURGISTARUNITED STATESMedical Devices

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 100M - 200M EUR

EBITDA range: 5M - 25M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of VISIONIX INTERNATIONAL by REVENIO GROUP CORPORATION are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: visionix international

Acquirer: revenio group corporation